3

4

5

6 7

8

9

11

12

13

14

15

16

17

181920

2122

23

24

25

26

2728

29

30

31

A bill to be entitled An act relating to delivery of health care services; creating a catastrophic pharmaceutical expense assistance program; providing eligibility; prescribing duties of the Agency for Health Care Administration and other entities; providing for rules; requiring a report; requiring pharmacies that participate in the program or in Medicaid to agree to limitations on compensation; providing for certain professional regulatory boards to adopt rules to discourage their respective practitioners from accepting certain types of compensation from pharmaceutical manufacturers; requiring disclosure of certain information relating to such compensation; providing legislative intent; providing appropriations; providing an effective date. Be It Enacted by the Legislature of the State of Florida: Section 1. Catastrophic pharmaceutical expense assistance.--(1) PROGRAM ESTABLISHED. -- There is established a program to provide financial assistance to low-income elderly individuals with catastrophic pharmaceutical expenses. (2) ELIGIBILITY.--Eligibility is limited to those individuals who do not qualify for assistance under the Medicaid program and who:

(a) Are over the age of 65;

- (b) Have an income at or below 250 percent of the federal poverty level; and
- (c) Have out-of-pocket prescription expenses that exceed or are projected to exceed 10 percent of their annual income, after payments by other liable entities are deducted.
- (3) BENEFITS.--Medications covered under the catastrophic pharmaceutical expense assistance program are those covered under the Medicaid program in section 409.906(20), Florida Statutes. Payments shall be for the total amount of prescription drug expenses above 10 percent of an individual's annual income.
- expense assistance program shall be administered by the Agency for Health Care Administration, in consultation with the Department of Elderly Affairs. To the extent possible, administration of the program, including eligibility determination, claims processing, and reporting, shall use existing administrative mechanisms, including the Medicaid fiscal agent system and area agencies on aging.
- (a) The Agency for Health Care Administration shall make payments for prescription drugs on behalf of eligible individuals.
- (b) The Agency for Health Care Administration and the Department of Elderly Affairs shall develop a single-page application for the catastrophic pharmaceutical expense assistance program.
- (c) The Agency for Health Care Administration shall, by rule, establish eligibility requirements, limits on participation, benefit limitations, a requirement for generic drug substitution, and other program parameters comparable to

those of the Medicaid program for the catastrophic pharmaceutical expense assistance program.

- (d) By January 1 of each year, the Agency for Health
  Care Administration shall report to the Legislature on the
  operation of the program. The report shall include information
  on the number of individuals served, use rates, and
  expenditures under the program. The report shall also address
  the impact of the program on reducing unmet pharmaceutical
  drug needs among the elderly and recommend programmatic
  changes.
- (5) NONENTITLEMENT.--The catastrophic pharmaceutical expense assistance program is not an entitlement and shall be the payor of last resort.

Section 2. Medicare prescription discount program.--As a condition of participation in the Florida Medicaid program or the catastrophic pharmaceutical expense assistance program, a pharmacy must agree that the charge to any Medicare beneficiary showing a Medicare card when presenting a prescription shall be no greater than the amount paid to that pharmacy for ingredients and dispensing under the Florida Medicaid program, plus 2.5 percent of the Medicaid payment for the ingredients of the prescription.

Section 3. The Legislature recognizes that the state has a compelling interest in maintaining the integrity of health care professions. The Legislature finds that physicians and other health care practitioners have a fiduciary responsibility to act in the best interests of their patients, who place their trust in, and are dependent on, the professional expertise of health care practitioners when seeking their services. The Legislature finds that the nature of the relationship between the patient and the health care

practitioner and the underlying trust in that relationship
prompt the need for guidelines to avoid the receipt by health
care practitioners of gifts, payments, subsidies, or other
financial inducements from pharmaceutical manufacturers which
adversely shape the health care practitioners' independent
professional judgment and which undermine their patients'
access to treatment, course of care, and clinical outcomes.

- (1) The Board of Medicine, the Board of Osteopathic Medicine, the Board of Podiatric Medicine, and the Board of Dentistry shall adopt, by rule, guidelines to discourage health care practitioners under their respective jurisdictions from accepting gifts, payments, subsidies, or other financial inducements from pharmaceutical manufacturers which may undermine the practitioners' independent professional judgment. Any gift, payment, or other financial inducement that a health care practitioner receives from a pharmaceutical manufacturer should primarily entail a benefit to his or her patients and should not be of substantial value. For purposes of this section, a gift, payment, subsidy, or other financial inducement does not include complimentary samples of medicinal drugs.
- about their care and to assist the health care practitioner in avoiding the receipt of gifts, payments, subsidies, or other financial inducements from pharmaceutical manufacturers which may not be justified, the Board of Medicine, the Board of Osteopathic Medicine, the Board of Podiatric Medicine, and the Board of Dentistry each shall require each health care practitioner under its regulatory jurisdiction to disclose to the Department of Health, as a condition of license renewal, the receipt of gifts, payments, subsidies, or other financial

inducements from pharmaceutical manufacturers which conflict with that health care practitioner's duty of loyalty to his or her patients.

Section 4. There is appropriated to the Agency for Health Care Administration the sum of \$15,244,200 from the Medical Care Trust Fund and the sum of \$11,755,800 from the General Revenue Fund to provide Medicaid for services for persons who are eligible under section 409.904(1), Florida Statutes, and whose incomes are greater than 90 percent of the federal poverty level but no greater than 100 percent of the federal poverty level.

Section 5. There is appropriated the sum of \$42 million from the General Revenue Fund to the Agency for Health Care Administration for the purpose of implementing section 1 relating to the catastrophic pharmaceutical expense assistance program.

Section 6. There is appropriated the sum of \$1 million from the General Revenue Fund to the Agency for Health Care

Administration to develop a computerized system that allows participating pharmacies to determine allowable maximum payments for prescription drugs under section 2.

Section 7. This act shall take effect upon becoming a law.

LEGISLATIVE SUMMARY Creates a catastrophic pharmaceutical expense assistance program to assist elderly persons meeting established criteria in paying for prescription drugs. Requires pharmacies participating in the program or in Medicaid to limit their compensation for drugs. Requires the Board of Medicine, the Board of Osteopathic Medicine, the Board of Podiatric Medicine, and the Board of Dentistry to adopt rules to discourage the professionals under their jurisdictions from accepting compensation from pharmaceutical manufacturers which would undermine independent professional judgment. Requires professionals receiving such compensation to report the compensation annually to the Department of Health.